Veradermics MANE
NYSE MANE
$120.65 -0.58 (-0.48%)
As of: Oct 1, 2026 · 10:53 AM EDT

Veradermics (MANE) Income from Continuing Operations (2025 - 2026)

Updated

Veradermics (MANE) recorded Income from Continuing Operations of -$23.5 million in Q2 2026, compared with -$15.65 million a year earlier.

Analysis

Veradermics (MANE) Income from Continuing Operations (2025 - 2026) Analysis & Trends

On a TTM basis, Veradermics' Income from Continuing Operations came in at -$78.78 million as of Jun 30, 2026; for FY2025, it came in at -$70 million.

  • Across earlier years, Income from Continuing Operations came in at -$26.49 million in FY2024.
  • Quarterly Income from Continuing Operations has ranged from -$27.23 million in Q1 2026 to -$12.4 million in Q1 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 5.53 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 3.62 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 5.28 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 3.09 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -10.50 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -246.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 1.10 Bn
10 Veradermics 5.07 Bn 5.07 Bn - -23.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -23.50 Mn
Mar 31, 2026 -27.23 Mn
Jun 30, 2025 -15.65 Mn
Mar 31, 2025 -12.40 Mn
API Access

Veradermics Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=MANE&period=max&api_key=YOUR_API_KEY